Literature DB >> 15571796

Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization.

Stella B Somiari1, Craig D Shriver, Jing He, Kishan Parikh, Rick Jordan, Jeffrey Hooke, Hai Hu, Brenda Deyarmin, Susan Lubert, Lisa Malicki, Caroline Heckman, Richard I Somiari.   

Abstract

Array-comparative genomic hybridization (a-CGH) is a molecular cytogenetic technique for detection of multiple chromosomal abnormalities in genomic DNA samples. Using an a-CGH with 287 probes, we examined 14 cases of breast infiltrating ductal carcinoma (IDCA) that had previously been classified by fluorescent in situ hybridization (FISH) as either human epidermal growth factor receptor-2 positive (HER2+) or HER2- and analyzed the data by hierarchical, K-means, and principal component analyses. The aim of the study was to identify the genetic abnormalities that are present in breast IDCAs and determine if the global status of 287 cytogenetic locations could be used as a more objective method for breast IDCA classification. Concordance between FISH and a-CGH at the HER2 locus was 78.6% (11/14). In general, a-CGH detected more abnormalities in HER2+ cases. In HER 2+ cases, chromosomes 1, 2, 3, 7, 9, 17, and 20 had more regions that showed statistically significant (P < or = 0.01) changes in DNA copy number. Among all the aberrant cytogenetic locations detected, 20q13, 7p12.3 approximately p12.1, and 17q23.2 approximately q25.3, which contain among others, genes for TNFRSF6B, EGFR, and TK1 showed statistically significant gains (P < or = 0.01) in 83, 66.7, and 50% of the HER2+ IDCA cases, respectively. Chromosome location 8q24.12 approximately q24.13 was the only region that showed consistent amplification in approximately 50% of the HER2- cases. Unsupervised hierarchical and K-means cluster analyses and principal component analysis using the DNA copy number status of 287 cytogenetic locations or the 177 cytogenetic locations that showed statistically significant differences revealed a cluster consisting of mainly HER2- IDCA cases. Even though this study demonstrates the usefulness of a-CGH in the rapid identification of aberrant DNA regions in tumor samples, we conclude that an array-CGH with more than 287 probes will be needed for a more precise mapping of DNA aberrations at the global level.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15571796     DOI: 10.1016/j.cancergencyto.2004.02.023

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

Review 1.  Navigating breast cancer: axon guidance molecules as breast cancer tumor suppressors and oncogenes.

Authors:  Gwyndolen C Harburg; Lindsay Hinck
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-08-05       Impact factor: 2.673

2.  Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.

Authors:  S Ram Kumar; Jasbir Singh; Guangbin Xia; Valery Krasnoperov; Loubna Hassanieh; Eric J Ley; Jeffrey Scehnet; Neil G Kumar; Debra Hawes; Michael F Press; Fred A Weaver; Parkash S Gill
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

3.  Breast cancer and protein biomarkers.

Authors:  Lay-Harn Gam
Journal:  World J Exp Med       Date:  2012-10-20

Review 4.  Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis.

Authors:  Frank A Orlando; Kevin D Brown
Journal:  Ann Surg Oncol       Date:  2009-05-19       Impact factor: 5.344

5.  Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma.

Authors:  Lisa M Davis; Cole Harris; Lei Tang; Patti Doherty; Peter Hraber; Yumiko Sakai; Therese Bocklage; Katie Doeden; Bryan Hall; John Alsobrook; Ian Rabinowitz; Thomas M Williams; John Hozier
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

Review 6.  Array-CGH and breast cancer.

Authors:  Erik H van Beers; Petra M Nederlof
Journal:  Breast Cancer Res       Date:  2006-06-30       Impact factor: 6.466

7.  The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.

Authors:  Olga Aprelikova; Kenny Chen; Lara H El Touny; Constance Brignatz-Guittard; Justin Han; Tinghu Qiu; Howard H Yang; Maxwell P Lee; Min Zhu; Jeffrey E Green
Journal:  Clin Epigenetics       Date:  2016-04-14       Impact factor: 6.551

8.  Efficiency analysis of competing tests for finding differentially expressed genes in lung adenocarcinoma.

Authors:  Rick Jordan; Satish Patel; Hai Hu; James Lyons-Weiler
Journal:  Cancer Inform       Date:  2008-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.